Envoy Medical Receives Nasdaq Extension for Bid Price Compliance, Considers Reverse Split
COCH sits 90% above its 52-week low of $0.363 on light trading volume (0.3× avg).
Summary
Envoy Medical received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price rule, avoiding immediate delisting but indicating a potential reverse stock split.
Key Events · Corporate Governance and Compliance · COCH
-
Failed Bid Price Compliance
Envoy Medical did not meet the Nasdaq $1.00 minimum bid price requirement by the May 18, 2026 deadline, following an initial notice on November 19, 2025.
-
Granted 180-Day Extension
Nasdaq provided an additional 180-day period, until November 16, 2026, for the company to regain compliance, based on meeting other listing requirements.
-
Potential Reverse Stock Split
The company informed Nasdaq of its intention to cure the deficiency, including by effecting a reverse stock split if necessary.
Analysis · COCH · Industrial Applications And Services
Envoy Medical failed to meet Nasdaq's $1.00 minimum bid price requirement by the May 18, 2026 deadline. While this avoids immediate delisting, the company received a 180-day extension until November 16, 2026, and stated its intent to cure the deficiency, potentially through a reverse stock split. This signals continued struggles with its stock price and introduces the risk of a reverse split, which often carries negative investor sentiment.
At the time of this filing, COCH was trading at $0.69 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $54.5M. The 52-week trading range was $0.36 to $1.89. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.